189 related articles for article (PubMed ID: 21955084)
1. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
Ibrahim JG; Chen MH; Xia HA; Liu T
Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
[TBL] [Abstract][Full Text] [Related]
2. Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.
Chen MH; Ibrahim JG; Amy Xia H; Liu T; Hennessey V
Stat Med; 2014 Apr; 33(9):1600-18. PubMed ID: 24343859
[TBL] [Abstract][Full Text] [Related]
3. Bayesian design of noninferiority trials for medical devices using historical data.
Chen MH; Ibrahim JG; Lam P; Yu A; Zhang Y
Biometrics; 2011 Sep; 67(3):1163-70. PubMed ID: 21361889
[TBL] [Abstract][Full Text] [Related]
4. Bayesian adaptive D-optimal design with delayed responses.
Li J; Fu H
J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
[TBL] [Abstract][Full Text] [Related]
5. A practical Bayesian adaptive design incorporating data from historical controls.
Psioda MA; Soukup M; Ibrahim JG
Stat Med; 2018 Nov; 37(27):4054-4070. PubMed ID: 30033617
[TBL] [Abstract][Full Text] [Related]
6. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
7. Ecological-type inference in matched-pair studies with fixed marginal totals.
Barker LK; Griffin SO; Jeon S; Gray SK; Vidakovic B
Stat Med; 2011 Feb; 30(5):541-8. PubMed ID: 21312218
[TBL] [Abstract][Full Text] [Related]
8. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
9. Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.
Chen MH; Ibrahim JG; Zeng D; Hu K; Jia C
Biometrics; 2014 Dec; 70(4):1003-13. PubMed ID: 25041037
[TBL] [Abstract][Full Text] [Related]
10. Bayesian variable selection with joint modeling of categorical and survival outcomes: an application to individualizing chemotherapy treatment in advanced colorectal cancer.
Chen W; Ghosh D; Raghunathan TE; Sargent DJ
Biometrics; 2009 Dec; 65(4):1030-40. PubMed ID: 19210736
[TBL] [Abstract][Full Text] [Related]
11. Bayesian clinical trial design using historical data that inform the treatment effect.
Psioda MA; Ibrahim JG
Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
[TBL] [Abstract][Full Text] [Related]
12. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
13. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
14. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
15. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
16. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
17. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
Thall PF; Nguyen HQ; Braun TM; Qazilbash MH
Biometrics; 2013 Sep; 69(3):673-82. PubMed ID: 23957592
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a
Cefalu WT; Kaul S; Gerstein HC; Holman RR; Zinman B; Skyler JS; Green JB; Buse JB; Inzucchi SE; Leiter LA; Raz I; Rosenstock J; Riddle MC
Diabetes Care; 2018 Jan; 41(1):14-31. PubMed ID: 29263194
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian Meta-analysis Method for Estimating Risk Difference of Rare Events.
Tang Y; Tang Q; Yu Y; Wen S
J Biopharm Stat; 2018; 28(3):550-561. PubMed ID: 29053049
[TBL] [Abstract][Full Text] [Related]
20. Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.
Doi M; Takahashi F; Kawasaki Y
Stat Med; 2017 Dec; 36(30):4789-4803. PubMed ID: 28960376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
